Vifor Pharma (GNHAY) News Today $38.39 0.00 (0.00%) As of 01/12/2023 Add Compare Share Share Headlines Stock AnalysisBuy This Stock GNHAY Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Approval of delisting of Vifor Pharma AG's registered sharesOctober 12, 2022 | finance.yahoo.comCara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patientsAugust 20, 2022 | seekingalpha.comVifor Fresenius' rare autoimmune disease drug Tavneos gets UK NICE backingAugust 19, 2022 | seekingalpha.comEuropean Commission Commences Antitrust Investigation Against Vifor PharmaJune 20, 2022 | nasdaq.comEU regulators investigate Vifor Pharma over anti-competitive behaviourJune 20, 2022 | uk.finance.yahoo.comVifor Pharma Faces EU Antitrust InvestigationJune 20, 2022 | marketwatch.comEU antitrust regulators to probe if Vifor Pharma disparages rivalJune 20, 2022 | finance.yahoo.comUpdate on the timeline for Vifor Pharma tender offerMay 12, 2022 | finance.yahoo.com94th Vifor Pharma Group Annual General MeetingApril 26, 2022 | finance.yahoo.comAmerican Kidney Fund Announces Support from Vifor Pharma for Pruritus Education CampaignApril 2, 2022 | apnews.comAPublication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percentMarch 3, 2022 | finance.yahoo.comAkebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat LaunchFebruary 22, 2022 | finance.yahoo.comVifor Pharma appoints two new members to the Executive CommitteeFebruary 2, 2022 | finance.yahoo.comCordenPharma Completes Acquisition of Three Manufacturing Facilities from Vifor PharmaFebruary 1, 2022 | benzinga.comVFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitisJanuary 19, 2022 | finance.yahoo.comCSL BEHRING AG PUBLISHES OFFER PROSPECTUS ON PUBLIC TENDER OFFER FOR ALL PUBLICLY HELD SHARES OF VIFOR PHARMA LTD.January 18, 2022 | finance.yahoo.comVifor Pharma and American Regent announce settlement of Injectafer ® patent litigationDecember 20, 2021 | businesswire.comVifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharmaDecember 16, 2021 | finance.yahoo.comCSL Seals $11.7B Buyout Deal Of Vifor Pharma, Probably the Largest Healthcare Deal In 2021December 14, 2021 | benzinga.comVifor Pharma Surges Again as Board Recommends CSL Bid Valuing Equity at $11.7 BlnDecember 14, 2021 | marketwatch.comCSL Limited announces tender offer to acquire Vifor Pharma LtdDecember 14, 2021 | businesswire.comCSL stalked Vifor Pharma for a decadeDecember 14, 2021 | afr.comCSL buys Vifor Pharma in $16.4b dealDecember 14, 2021 | afr.comVifor Pharma: First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell diseaseDecember 10, 2021 | finanznachrichten.deFirst patient enrolled in phase-IIa study of vamifeport in patients with sickle cell diseaseDecember 10, 2021 | finance.yahoo.comAustralia's CSL in exclusive talks for $7 billion buyout of Swiss Vifor Pharma - reportDecember 2, 2021 | investing.comVifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrologyNovember 22, 2021 | finance.yahoo.comVifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AGNovember 22, 2021 | finance.yahoo.comCara Therapeutics, inc (CARA) Q3 2021 Earnings Call TranscriptNovember 8, 2021 | finance.yahoo.comVifor Pharma announces changes to its Executive CommitteeOctober 12, 2021 | finance.yahoo.com Get Vifor Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for GNHAY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNHAY Media Mentions By Week GNHAY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNHAY News Sentiment▼0.001.12▲Average Medical News Sentiment GNHAY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNHAY Articles This Week▼00▲GNHAY Articles Average Week Get the Latest News and Ratings for GNHAY and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Vifor Pharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies TGIFF News FFNTF News ABSCF News LBTSF News AZFL News ERBB News AVTBF News AVCNF News BIOYF News CBGL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:GNHAY) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vifor Pharma AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Vifor Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNHAY Stock Alerts